National Cancer Institute Notice of Closed Meetings, 43248-43249 [2020-15379]
Download as PDF
<![CDATA[
43248
Federal Register / Vol. 85, No. 137 / Thursday, July 16, 2020 / Notices
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1078, Bethesda, MD 20892, 301–594–7319,
khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: July 13, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–15375 Filed 7–15–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SARS–
COV–2 Serological Sciences Centers of
Excellence.
Date: August 17–18, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W530, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Shamala K. Srinivas,
Ph.D., Associate Director, Office of Referral,
Review, and Program Coordination, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W530, Rockville, MD 20850, 240–
276–6442, ss537t@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; K22
Transition Career Development Award.
Date: September 22, 2020.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
17:43 Jul 15, 2020
Jkt 250001
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
7W234, Rockville, MD 20850, 240–276–6368,
stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
(P50) I Review.
Date: September 22–23, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W244, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: John Paul Cairns, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W244,
Rockville, MD 20892, 240–276–5415
paul.cairns@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
(P50) II Review.
Date: September 23–24, 2020.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W116, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Klaus B. Piontek, Ph.D.,
Scientific Review Officer,Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room
7W116Rockville, MD 20850, 240–276–5413
klaus.piontek@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project I (PO1).
Date: September 24–25, 2020.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W618, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W618,
Rockville, MD 20850, 240–276–6611
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
(P50) III Review.
Date: September 24–25, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W122, Rockville, MD 20850 (Telephone
Conference Call).
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Contact Person: Anita T. Tandle, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W122,
Rockville, MD 20850, 240–276–5085,
tandlea@mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
J—Career Development.
Date: October 15–16, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: NCI Shady Grove, 9609 Medical
Center Drive, Room 7W624, Rockville, MD
20850 (Telephone Conference Call).
Contact Person: Tushar Deb, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W624, Rockville, MD 20850, 240–
276–6132, tushar.deb@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project (P01) Review Meeting II.
Date: October 15–16, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W120, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Majed M. Hamawy, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W120,
Rockville, MD 20850, 240–276–6457,
mh101v@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project III (P01).
Date: October 20–21, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W634, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Michael E. Lindquist,
Ph.D., Scientific Review Officer, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W634, Rockville, MD 20850, 240–
276–5735, mike.lindquist@nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
I—Transition to Independence.
Date: October 21–22, 2020.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W602, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Delia Tang, M.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
E:\FR\FM\16JYN1.SGM
16JYN1
Federal Register / Vol. 85, No. 137 / Thursday, July 16, 2020 / Notices
Institute, NIH, 9609 Medical Center Drive,
Room 7W602, Rockville, MD 20892, 240–
276–6456, tangd@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Molecular and Cellular Analysis
Technologies.
Date: November 4–5, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W246, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, MD 20850, 240–
276–5460, jfang@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 13, 2020.
Melanie J. Pantoja,
Program Analyst,Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–15379 Filed 7–15–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Interagency Coordinating Committee
on the Validation of Alternative
Methods Biennial Progress Report:
2018–2019; Availability of Report
National Institutes of Health,
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
The National Toxicology
Program (NTP) Interagency Center for
the Evaluation of Alternative
Toxicological Methods (NICEATM)
announces availability of the
Interagency Coordinating Committee on
the Validation of Alternative Methods
(ICCVAM) Biennial Progress Report:
2018–2019. This report, prepared in
accordance with requirements of the
ICCVAM Authorization Act of 2000,
describes activities and
accomplishments from January 2018
through December 2019.
ADDRESSES: The report is available at
https://ntp.niehs.nih.gov/iccvamreport/
2019/.
SUMMARY:
VerDate Sep<11>2014
17:43 Jul 15, 2020
Jkt 250001
Dr.
Nicole Kleinstreuer, Acting Director,
NICEATM, Division of NTP, NIEHS,
P.O. Box 12233, K2–17, Research
Triangle Park, NC 27709. Phone: 984–
287–3150, Email: nicole.kleinstreuer@
nih.gov. Hand Deliver/Courier address:
530 Davis Drive, Room K2032,
Morrisville, NC 27560.
SUPPLEMENTARY INFORMATION:
Background: The ICCVAM
Authorization Act of 2000 (42 U.S.C.
285l-3), established ICCVAM as a
permanent interagency committee of the
National Institute of Environmental
Health Sciences (NIEHS) under
NICEATM. ICCVAM’s mission is to
facilitate development, validation, and
regulatory acceptance of new and
revised regulatory test methods that
reduce, refine, or replace the use of
animals in testing while maintaining
and promoting scientific quality and the
protection of human health, animal
health, and the environment.
A provision of the ICCVAM
Authorization Act states that ICCVAM
shall prepare ‘‘reports to be made
available to the public on its progress
under this Act.’’ The tenth ICCVAM
biennial progress report describing
ICCVAM activities and
accomplishments from January 2018
through December 2019 is now
available.
Summary of Report Contents: Key
ICCVAM, ICCVAM agency, and
NICEATM accomplishments
summarized in the report include:
• Publication in January 2018 of a
strategic roadmap for incorporating new
approaches into safety testing of
chemicals and medical products in the
United States, and progress toward goals
described in the strategic roadmap.
• Development of the Collaborative
Acute Toxicity Modeling Suite, an
online resource for screening organic
chemicals for acute oral toxicity, and
expansion of NICEATM’s Integrated
Chemical Environment, which provides
curated data and tools for safety
assessment of chemicals.
• Initiatives by the U.S.
Environmental Protection Agency to
reduce animal use: A draft science
policy to reduce animal use for skin
sensitization testing for pesticide
registration, a plan to reduce vertebrate
animal testing for chemical safety
information required under the Toxic
Substances Control Act, and an agencywide directive to reduce mammal study
requests and funding 30% by 2025 and
completely eliminating them by 2035.
• Development of a strategic roadmap
by the Department of Defense to help its
laboratories better define their chemical
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
43249
assessment needs and collaborate on
development or refinement of
appropriate non-animal approaches for
testing.
• Implementation by the U.S. Food
and Drug Administration of its
predictive toxicity roadmap for
integrating predictive toxicology
methods into safety and risk
assessments.
Availability of Report: The report is
available at https://ntp.niehs.nih.gov/
iccvamreport/2019/. Links to
this report and all past ICCVAM annual
and biennial reports are available at
https://ntp.niehs.nih.gov/go/iccvam-bien.
Background Information on ICCVAM
and NICEATM: ICCVAM is an
interagency committee composed of
representatives from 16 federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
and integrated testing strategies with
regulatory applicability and promotes
the scientific validation and regulatory
acceptance of testing methods that more
accurately assess the safety and hazards
of chemicals and products and replace,
reduce, or refine (enhance animal wellbeing and lessen or avoid pain and
distress) animal use.
The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) establishes
ICCVAM as a permanent interagency
committee of NIEHS and provides the
authority for ICCVAM involvement in
activities relevant to the development of
alternative test methods. Additional
information about ICCVAM can be
found at https://ntp.niehs.nih.gov/go/
iccvam.
NICEATM administers ICCVAM,
provides scientific and operational
support for ICCVAM-related activities,
and conducts and publishes analyses
and evaluations of data from new,
revised, and alternative testing
approaches. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved testing approaches
applicable to the needs of U.S. Federal
agencies. NICEATM and ICCVAM
welcome the public nomination of new,
revised, and alternative testing
approaches for validation studies and
technical evaluations. Additional
information about NICEATM can be
found at https://ntp.niehs.nih.gov/go/
niceatm.
E:\FR\FM\16JYN1.SGM
16JYN1
]]>Agencies
[Federal Register Volume 85, Number 137 (Thursday, July 16, 2020)]
[Notices]
[Pages 43248-43249]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15379]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; SARS-COV-2 Serological Sciences Centers of Excellence.
Date: August 17-18, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W530, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Shamala K. Srinivas, Ph.D., Associate Director,
Office of Referral, Review, and Program Coordination, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W530, Rockville, MD 20850, 240-276-6442,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; K22 Transition Career Development Award.
Date: September 22, 2020.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W234, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Adriana Stoica, Ph.D., Scientific Review
Officer, Resources and Training Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, 7W234, Rockville, MD 20850, 240-276-6368,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI SPORE (P50) I Review.
Date: September 22-23, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W244, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: John Paul Cairns, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W244, Rockville, MD 20892, 240-276-5415
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI SPORE (P50) II Review.
Date: September 23-24, 2020.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W116, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Klaus B. Piontek, Ph.D., Scientific Review
Officer,Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W116Rockville, MD 20850, 240-276-5413
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Program Project I (PO1).
Date: September 24-25, 2020.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W618, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Mukesh Kumar, Ph.D., Scientific Review Officer,
Research Program Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W618, Rockville, MD 20850, 240-276-6611 [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI SPORE (P50) III Review.
Date: September 24-25, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W122, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Anita T. Tandle, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W122, Rockville, MD 20850, 240-276-5085,
[email protected].
Name of Committee: National Cancer Institute Initial Review
Group; Subcommittee J--Career Development.
Date: October 15-16, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: NCI Shady Grove, 9609 Medical Center Drive, Room 7W624,
Rockville, MD 20850 (Telephone Conference Call).
Contact Person: Tushar Deb, Ph.D., Scientific Review Officer,
Resources and Training Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W624, Rockville, MD 20850, 240-276-6132,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Program Project (P01) Review Meeting II.
Date: October 15-16, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W120, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Majed M. Hamawy, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W120, Rockville, MD 20850, 240-276-6457,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Program Project III (P01).
Date: October 20-21, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W634, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Michael E. Lindquist, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W634, Rockville, MD 20850, 240-276-5735,
[email protected].
Name of Committee: National Cancer Institute Initial Review
Group; Subcommittee I--Transition to Independence.
Date: October 21-22, 2020.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W602, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Delia Tang, M.D., Scientific Review Officer,
Resources and Training Review Branch, Division of Extramural
Activities, National Cancer
[[Page 43249]]
Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, MD
20892, 240-276-6456, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Innovative Molecular and Cellular Analysis Technologies.
Date: November 4-5, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W246, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Jun Fang, Ph.D., Scientific Review Officer,
Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W246, Rockville, MD 20850, 240-276-5460,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 13, 2020.
Melanie J. Pantoja,
Program Analyst,Office of Federal Advisory Committee Policy.
[FR Doc. 2020-15379 Filed 7-15-20; 8:45 am]
BILLING CODE 4140-01-P
